Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 08/15/24
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development UpdateGlobeNewsWire • 08/01/24
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024GlobeNewsWire • 07/23/24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/14/24
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024GlobeNewsWire • 05/09/24
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsGlobeNewsWire • 04/18/24
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042GlobeNewsWire • 03/20/24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateGlobeNewsWire • 03/07/24
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024GlobeNewsWire • 02/26/24
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/05/24
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerGlobeNewsWire • 01/04/24
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone DeficiencyGlobeNewsWire • 11/21/23
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in NovemberGlobeNewsWire • 11/20/23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development UpdatesGlobeNewsWire • 11/07/23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary EndpointsGlobeNewsWire • 11/07/23
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual MeetingGlobeNewsWire • 09/26/23
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual MeetingGlobeNewsWire • 09/14/23
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic LandscapeGlobeNewsWire • 08/22/23